Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Institutional Perspectives in Cancer- GI: Chaired by Anne M Noonan, MBBCh

June 22nd 2022

Institutional Perspectives in Cancer- GI: Chaired by Anne M Noonan, MBBCh

Dr. Botta on the Rationale of Investigating CT041 in Gastric and Pancreatic Cancers

June 19th 2022

Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. Khan on the Rationale of Examining Disparate Outcomes in GI Tract Cancer Surgery

June 19th 2022

Sajid A. Khan MD, FACS, FSSO, discusses the rationale of examining disparate outcomes in gastrointestinal tract cancer surgery.

Efforts Are Needed to Address the Enigmatic Rise of Young-Onset Gastrointestinal Cancers

June 16th 2022

Despite a steady decline in incidence and mortality rates of many cancers among older individuals in the United States and other high-income countries, an alarming rise in young-onset gastrointestinal cancers has simultaneously occurred.

Overview of Molecular Testing in Colorectal Cancer

June 15th 2022

Jaclyn Hechtman, MD, provides an overview of the history of molecular testing in colorectal cancer and how testing has evolved.

Dr. Kahn on Next Steps on Examining Racial Disparities in GI Cancer

June 15th 2022

Sajid A Khan MD, FACS, FSSO, discusses next steps in examining racial disparities in gastrointestinal tract cancer.

Nivolumab/Ipilimumab and Nivolumab/Chemo Indications Enhance ESCC Treatment Landscape

June 15th 2022

The approval of 2 nivolumab-containing combinations for patients with advanced or metastatic esophageal squamous cell carcinoma have opened the doors for immunotherapy to enter the landscape for this population allowing clinicians options to help patients to meet their individual treatment goals.

Sotorasib Produces Encouraging Antitumor Activity in Heavily Pretreated KRAS G12C–Mutated Pancreatic Cancer

June 14th 2022

Sotorasib demonstrated clinically meaningful activity and acceptable tolerability in heavily pretreated patients with KRAS G12C–mutated advanced pancreatic cancer, according to date from the single-arm, phase 1/2 CodeBreak 100 trial.

Insights on Existing and Prospective Second-line Treatment Strategies for Patients With ESCC

June 14th 2022

Thoughtful discussion of existing and emerging second-line treatment options for patients with metastatic ESCC

First-line Treatment Approaches and Considerations for Patients With Metastatic ESCC

June 14th 2022

Focusing on metastatic ESCC, John Marshall, MD, discusses selecting appropriate first-line treatment strategies for patients.

Hua Highlights Innovative Research With Immunotherapy in NETs

June 9th 2022

Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evaluating anti-CDH17 CAR T cells in this disease.

Trends and Disparities in Treatment Approaches for Patients With Locoregional ESCC

June 8th 2022

Shared insights on contemporary approaches to treating localized ESCC and existing racial disparities in treatment.

A Survey of Patient Presentation, Testing, and Diagnosis in ESCC

June 8th 2022

Broad discussion from expert John Marshall, MD, on the current standards of diagnosis care in esophageal squamous cell carcinoma (ESCC).

Gastrointestinal Cancers Recap at ASCO 2022: Dr Tanios Bekaii-Saab

June 6th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

CT041 CAR T-cell Therapy Elicits Manageable Toxicity and Durable Response in Gastric/GEJ Cancer

June 5th 2022

CT041, a Claudin18.2–specific CAR T-cell therapy, demonstrated a manageable safety profile in patients with previously treated, CLDN18.2-positive advanced gastric/gastroesophageal junction cancer, with a majority of patients achieving partial response or stable disease.

Nimotuzumab Plus Gemcitabine Improves Survival in KRAS Wild-Type Pancreatic Cancer

June 3rd 2022

Dr. Ajani on the FDA Approvals of Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab in ESCC

June 2nd 2022

Jaffer A. Ajani, MD, discusses how the FDA approvals of first-line nivolumab plus chemotherapy and nivolumab plus ipilimumab in advanced or metastatic esophageal squamous cell carcinoma will improve treatment in this setting.

OncLive Honors 13 Cancer Care Pioneers

June 2nd 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Second-Line Pemigatinib May Provide PFS Benefit in Cholangiocarcinoma With FGFR2 Fusions/Rearrangements

June 2nd 2022

Second-line treatment with pemigatinib may be linked with prolonged progression-free survival compared with other systemic therapies in patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements.

Novel Second-line Treatments Expand Therapeutic Options in Gastrointestinal Cancers

June 1st 2022

Kelsey Klute, MD, discusses the importance of frontline checkpoint inhibitors in advanced gastric cancer, the need for predictive biomarkers in hepatocellular carcinoma, and research investigating immunotherapy in HER2-negative gastric and esophagus cancer and esophagus and gastroesophageal junction cancer.